How to buy Intracellular Th stock (ITCI)

Intracellular Th is a drug manufacturers - specialty & generic business based in the US. Intracellular Th shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $83.45 – an increase of 0.51% over the previous week. Intracellular Th employs 610 staff and has a trailing 12-month revenue of around $613.7 million.

Our top picks for where to buy Intracellular Th stock

Buy Intracellular Th stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Intracellular Th stock price (NASDAQ: ITCI)

Use our graph to track the performance of ITCI stocks over time.

Intracellular Th shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$83.45
52-week range	$62.78 - $93.45
50-day moving average more info button	$82.72
200-day moving average more info button	$74.39
Wall St. target price	$103.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.87

Is it a good time to buy Intracellular Th stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intracellular Th price performance over time

Historical closes compared with the close of $83.45 from 2024-12-20

1 week (2024-12-13)	0.51%
1 month (2024-11-22)	-2.61%
3 months (2024-09-20)	7.52%
6 months (2024-06-21)	8.97%

1 year (2023-12-22)	18.62%
2 years (2022-12-22)	61.79%
3 years (2021-12-22)	67.87%
5 years (2019-12-20)	570.82%

Intracellular Th financials

Revenue TTM	$613.7 million
Gross profit TTM	$95.2 million
Return on assets TTM	-7.45%
Return on equity TTM	-9.9%
Profit margin	-14.07%
Book value	$10.80
Market Capitalization more info button	$9.2 billion

TTM: trailing 12 months

Intracellular Th share dividends

We're not expecting Intracellular Th to pay a dividend over the next 12 months.

Intracellular Th share price volatility

Over the last 12 months, Intracellular Th's shares have ranged in value from as little as $62.78 up to $93.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intracellular Th's is 0.973. This would suggest that Intracellular Th's shares are less volatile than average (for this exchange).

Intracellular Th overview

Intra-Cellular Therapies, Inc. , a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Frequently asked questions

What percentage of Intracellular Th is owned by insiders or institutions?
Currently 2.331% of Intracellular Th shares are held by insiders and 96.345% by institutions. How many people work for Intracellular Th?
Latest data suggests 610 work at Intracellular Th. When does the fiscal year end for Intracellular Th?
Intracellular Th's fiscal year ends in December. Where is Intracellular Th based?
Intracellular Th's address is: 430 East 29th Street, New York, NY, United States, 10016 What is Intracellular Th's ISIN number?
Intracellular Th's international securities identification number is: US46116X1019 What is Intracellular Th's CUSIP number?
Intracellular Th's Committee on Uniform Securities Identification Procedures number is: 46116X101